Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
The latest update is out from GNI Group ( (JP:2160) ).
GNI Group Ltd.’s subsidiary, Gyre Therapeutics, has successfully completed a Phase 3 clinical trial in China for their liver fibrosis treatment drug, F351. The trial’s success, demonstrating significant fibrosis regression, positions the company favorably in the Chinese market for chronic hepatitis B-related liver fibrosis treatments.
The most recent analyst rating on (JP:2160) stock is a Buy with a Yen3700.00 price target. To see the full list of analyst forecasts on GNI Group stock, see the JP:2160 Stock Forecast page.
More about GNI Group
GNI Group Ltd. operates in the pharmaceutical industry, focusing on developing innovative treatments for various medical conditions. Its primary products and services include therapeutics for liver fibrosis and other chronic diseases, with a significant market focus in China.
Average Trading Volume: 2,353,867
Technical Sentiment Signal: Hold
Current Market Cap: Yen124.8B
See more insights into 2160 stock on TipRanks’ Stock Analysis page.
Trending Articles:
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue